Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.~* The patient has active disease at both Screening and Baseline, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) \>28 mm in the local laboratory. 2. CRP \>7 mg/L in the central laboratory~* Patient had an inadequate response to at least one DMARD (traditional or biologic) due to lack of efficacy or toxicity.~* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Patient has washed out of all DMARDs other that antimalarials~Exclusion Criteria:~* Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3.0 x 109/L; 3. Absolute neutrophil count \<1.2 x 109/L; 4. Platelet count \<100 x 109/L~* History of any other autoimmune rheumatic disease other than Sjogren's syndrome~* No malignancy or history of malignancy.~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active 5mg (Type: EXPERIMENTAL): None
- Active 10 mg (Type: EXPERIMENTAL): None
- Placebo Sequence 1 (Type: PLACEBO_COMPARATOR): None
- Placebo Sequence 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).